Question 1

What is SLU-PP-332 and what is it commonly researched for?

Accepted Answer

SLU-PP-332 is a synthetic small-molecule pan-ERR agonist developed in the Thomas Burris lab. It activates the same nuclear receptors that endurance exercise activates, which is why it is often described as an exercise mimetic. Published mouse studies report increased treadmill endurance, fat-mass reduction in obese mice, improved cardiac function in heart-failure models, and reduced inflammation in aging-kidney models. Despite the 'peptide' label used in many product listings, SLU-PP-332 is not a peptide — it is a small organic molecule.

Question 2

What is the starting dose of SLU-PP-332?

Accepted Answer

There is no human-validated starting dose. Published murine studies used 25-50 mg/kg intraperitoneal injection once or twice daily. Two community patterns circulate for humans: a low-dose oral pattern (250 mcg to ~1.5 mg once daily) using small-strength vendor capsules, and a higher pattern anchored to the supplier's 50 mg tablet (1 tablet daily). A separate high-dose extrapolation lands near 650 mg/day based on mouse-to-human allometric scaling, but no human has been studied at any dose. None of these are dosing recommendations.

Question 3

How are SLU-PP-332 tablets typically dosed?

Accepted Answer

The current featured supplier carries SLU-PP-332 as a 50 mg oral tablet in a 60-tablet bottle. Community oral protocols range from a 25 mg split-tablet pattern to a 50 mg or 100 mg daily pattern. Oral bioavailability in humans has not been formally published, so any tablet dose is a community pattern, not a clinically validated dose. See the PepPal supplier rankings for broader sourcing context.

Question 4

What is the difference between SLU-PP-332 tablets and injectable vials?

Accepted Answer

Tablets are easier to handle, need no reconstitution, and dose by bottle and tablet count. Injectable vials are the format used in every published animal study, but those used intraperitoneal injection in mice — not subcutaneous injection in humans. Community injectable users reconstitute a 5 mg or 10 mg vial with bacteriostatic water and inject subcutaneously. Oral bioavailability and pharmacokinetics for SC human administration are not published, so there is no clinical answer to which format is more effective.

Question 5

What is SLU-PP-332's half-life?

Accepted Answer

A formal human pharmacokinetic half-life has not been published. In the Billon 2023 paper, mice given 30 mg/kg IP still showed measurable plasma and muscle concentrations at 6 hours post-injection, which helps explain why twice-daily dosing was used in efficacy studies.

Question 6

How do you reconstitute SLU-PP-332 injection vials?

Accepted Answer

For a 5 mg vial, adding 2 mL of bacteriostatic water gives a 2,500 mcg/mL concentration where a 500 mcg dose equals 20 units on a U-100 insulin syringe. Other vial sizes and concentrations are tabulated in the reconstitution section above. For exact draw volumes, use the Pep Pal reconstitution calculator .

Question 7

Is SLU-PP-332 FDA-approved?

Accepted Answer

No. SLU-PP-332 is not approved by the FDA for any indication. It is sold by research suppliers as a research-use compound. There is no registered or completed human clinical trial program on ClinicalTrials.gov as of June 2026.

Question 8

What are the most common observed effects of SLU-PP-332?

Accepted Answer

There is no human observed effect dataset. Published mouse studies did not report overt toxicity, liver-enzyme issues, or sickness-related weight loss at 25-50 mg/kg IP for up to 8 weeks. Community reports describe mild appetite changes, sleep disturbance, and increased resting heart rate in some users, but these are uncontrolled observations.

Question 9

Why did my reconstituted SLU-PP-332 turn yellow?

Accepted Answer

A faint pale-yellow tint can occur with small-molecule compounds in aqueous solution, but a deepening yellow shade often indicates oxidation or degradation from light or temperature excursions. If the color shifts noticeably from the initial appearance, treat the vial as potentially degraded and contact the supplier rather than continuing use. Formal stability data for community reconstitution conditions has not been published.

Question 10

How does SLU-PP-332 compare to MOTS-c and AOD-9604?

Accepted Answer

SLU-PP-332 works at the nuclear-receptor level through ERRα / β / γ. MOTS-c is a mitochondrial-derived peptide with AMPK-linked signaling, and AOD-9604 is a GH-fragment-derived lipolysis compound. SLU-PP-332 has the strongest preclinical exercise-mimetic signature of the three, but zero human clinical data.

Question 11

Can SLU-PP-332 be stacked with other compounds like MK-677?

Accepted Answer

No human study has evaluated SLU-PP-332 in combination with any other compound. Theoretical pairings appear in community discussion, but none are clinically validated, and combining experimental compounds compounds the unknowns. PDP does not provide stacking recommendations involving SLU-PP-332. For broader stacking context, see the PepPal peptide stacking guide .

Question 12

What is the maximum dose of SLU-PP-332 studied?

Accepted Answer

In published mouse studies, 50 mg/kg IP twice daily for 28 days is the highest-dose, longest-duration regimen reported in peer-reviewed literature. Human-equivalent-dose extrapolation from that protocol lands around 650 mg/day for an 80 kg adult, but no human has been studied at any dose in a published trial. This is not a dosing recommendation.

Question 13

Is the information on this page medical advice?

Accepted Answer

No. Everything on this page is educational research context. SLU-PP-332 is a preclinical research compound with no FDA-approved indication and no human trial program. Nothing on this page is intended as a personal dosing recommendation or as treatment guidance. Work with a qualified clinician for individual decisions.

Phase	Daily reference amount	Units / volume
Weeks 1–2	1250 mcg	625 mcg
Weeks 3–8	2500 mcg	1250 mcg

SLU-PP-332.

Calculated volume reference

Cited protocol & reconstitution guide